Anti-CD79A monoclonal antibody, clone IN58/B0

Name: Anti-CD79A monoclonal antibody, clone IN58/B0
SKU: DCABH-8498
Rating: 5 (1 reviews)

Mouse anti-Human CD79A monoclonal antibody for ICC/IF, IHC-P, WB, FC

Write a review

COA

SDS

Datasheet

Summary

Specifications

Antibody Isotype

IgG1

Clone

IN58/B0

Species Reactivity

Mouse; Rat; Cow; Human; Pig; Monkey

Immunogen

Synthetic peptide: GTYQDVGSLNIADVQ, corresponding to C terminal amino acids 208-222 of Human CD79a.

Conjugate

Unconjugated

Applications

Application Notes

IHC-P: 0.5 - 1 μg/ml; WB: 0.5 - 1 μg/ml; Flow Cyt: 0.01μg for/10⁶ cells.

Target

Alternative Names

CD79A; CD79a molecule, immunoglobulin-associated alpha; CD79A antigen (immunoglobulin associated alpha) , IGA; B-cell antigen receptor complex-associated protein alpha chain; MB 1; ig-alpha; MB-1 membrane glycoprotein; surface IgM-associated protein; CD79

Entrez Gene ID

973

UniProt ID

P11912

Product Background

Antigen Description

Required in cooperation with CD79B for initiation of the signal transduction cascade activated by binding of antigen to the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Also required for BCR surface expression and for efficient differentiation of pro- and pre-B-cells. Stimulates SYK autophosphorylation and activation. Binds to BLNK, bringing BLNK into proximity with SYK and allowing SYK to phosphorylate BLNK. Also interacts with and increases activity of some Src-family tyrosine kinases. Represses BCR signaling during development of immature B cells.

Pathway

Adaptive Immune System, organism-specific biosystem; Antigen Activates B Cell Receptor Leading to Generation of Second Messengers, organism-specific biosystem; B Cell Receptor Signaling Pathway, organism-specific biosystem; B cell receptor signaling pathway, organism-specific biosystem; B cell receptor signaling pathway, conserved biosystem; BCR signaling pathway, organism-specific biosystem; Immune System, organism-specific biosystem;

Citations

Have you cited DCABH-8498 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Emerging molecular therapeutic targets for cholangiocarcinoma

JOURNAL OF HEPATOLOGY

Authors: Rizvi, Sumera; Gores, Gregory J.

Abstract

Cholangiocarcinomas (CCAs) are diverse epithelial tumors arising from the liver or large bile ducts with features of cholangiocyte differentiation. CCAs are classified anatomically into intrahepatic (iCCA), perihilar (pCCA), and distal CCA (dCCA). Each subtype has distinct risk factors, molecular pathogenesis, therapeutic options, and prognosis. CCA is an aggressive malignancy with a poor overall prognosis and median survival of less than 2 years in patients with advanced disease. Potentially curative surgical treatment options are limited to the subset of patients with early-stage disease. Presently, the available systemic medical therapies for advanced or metastatic CCA have limited therapeutic efficacy. Molecular alterations define the differences in biological behavior of each CCA subtype. Recent comprehensive genetic analysis has better characterized the genomic and transcriptomic landscape of each CCA subtype. Promising candidates for targeted, personalized therapy have emerged, including potential driver fibroblast growth factor receptor (FGFR) gene fusions and somatic mutations in isocitrate dehydrogenase (IDH) 1/2 in iCCA, protein kinase cAMP-activated catalytic subunit alpha (PRKACA) or beta (PRKACB) gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma. A precision genomic medicine approach is dependent on an enhanced understanding of driver mutations in each subtype and stratification of patients according to their genetic drivers. We review the current genomic landscape of CCA, the potentially actionable molecular aberrations in each CCA subtype, and the role of immunotherapy in CCA. (C) 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Molecular Characteristics of Biliary Tract and Primary Liver Tumors

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA

Authors: Tsai, Susan; Gamblin, T. Clark

Abstract

With the recent decline in cost of high-throughput next-generation sequencing, detailed characterization of biliary tract and primary liver tumors continues to evolve. Recent studies have elucidated molecular signatures that reflect distinct pathways of carcinogenesis reflective of viral, parasitic, and toxin-related etiologic factors. With greater elucidation of the molecular pathogenesis of disease, novel targets that may be potential clinically actionable continue to be identified.